Afrezza is a fast-acting insulin for people with diabetes. Instead of a shot, it is a powder you breathe in through a small inhaler at the start of a meal. It works like the insulin your body makes, helping move sugar from your blood into your cells.
Every report comes from a Lived member, sent anonymously.
Have you tried Afrezza (Inhaled Insulin) for Type 1 Diabetes?
Afrezza is a fast-acting form of human insulin that is breathed in as a dry powder through a small inhaler, rather than injected. It is a mealtime insulin, taken at the start of a meal to control the rise in blood sugar that eating causes. It is approved in the US for adults and children 6 years and older with type 1 or type 2 diabetes. Afrezza covers meals only. People with type 1 diabetes still need a long-acting (basal) insulin for their background, between-meal needs, and many people with type 2 diabetes use it alongside other diabetes medicines. Its main appeal is fewer injections. Because the powder goes into the lungs, it is not suitable for everyone, and lung health shapes who can use it.
Insulin is the hormone that moves sugar from the blood into muscle and fat cells and tells the liver to stop releasing stored sugar. In diabetes, the body makes too little insulin or responds poorly to it, so blood sugar runs high after meals. When Afrezza is inhaled, the insulin is absorbed through the lungs into the bloodstream quickly. In studies it began lowering blood sugar about 12 minutes after a dose, peaked within about an hour, and wore off sooner than injected mealtime insulins: roughly 1.5 hours for a small dose and up to about 4.5 hours for a large one. That short, early action is meant to match the meal itself, but the effect varies from person to person and from day to day.
Afrezza comes in single-use, color-coded cartridges of 4 units (blue), 8 units (green) and 12 units (yellow). A cartridge is placed in the inhaler and inhaled in one deep breath at the beginning of each meal. Larger doses use more than one cartridge. A care team member trains each person, or a caregiver, before the first dose; children 10 and older may then take it themselves if the clinician agrees. Afrezza units do not match injected insulin units one for one. Someone switching from injected mealtime insulin usually needs a higher Afrezza number for the same meal, so the starting dose should come from the prescriber rather than a direct swap. Doses are then adjusted using blood sugar readings, and more frequent checks are needed while the dose is being settled. People with type 1 diabetes must keep taking their basal insulin. Technique affects how much insulin is delivered. Once a cartridge is loaded, the inhaler should stay level; turning it upside down, shaking it or dropping it before inhaling can waste the dose, and the cartridge should then be replaced. Each inhaler is replaced after 15 days, and cartridges taken from the refrigerator should sit at room temperature for about 10 minutes first.
Low blood sugar (hypoglycemia) is the most common side effect, as with any insulin. Signs include shakiness, sweating, hunger, a fast heartbeat, dizziness, headache, irritability and confusion. A mild or moderate low is usually treated with a quick source of carbohydrate such as glucose tablets or juice, and Afrezza should not be taken during a low. Because Afrezza acts early and fades quickly, lows tend to happen sooner after a meal than with injected insulin. Severe low blood sugar, when someone passes out, has a seizure or cannot safely eat or drink, needs glucagon (a hormone that raises blood sugar, given by spray or injection by someone nearby) if it is available. Call 911 if there is no glucagon or the person does not wake up soon after it. Never put food or drink in the mouth of someone who is not awake. It is worth asking whether a glucagon kit is needed. Cough is very common, affecting roughly a quarter to nearly a third of people in studies, and throat irritation, headache and mild stomach upset also occur. Cough often happens just after inhaling. Afrezza also causes a small drop in lung function that shows up in the first few months, which is why breathing tests continue during treatment. Wheezing or trouble breathing after a dose should be reported to the care team right away. A severe allergic reaction is rare, and anyone who has had one to human insulin or to Afrezza's inactive ingredients should not use it. Swelling of the face, tongue or throat, trouble breathing, or a rash over the whole body needs emergency medical help (call 911).
The most important warning is about the lungs. Afrezza can cause sudden narrowing of the airways (bronchospasm) in people with chronic lung disease, so it must not be used by anyone with asthma or COPD (chronic obstructive pulmonary disease, which includes emphysema and chronic bronchitis). Before starting, everyone has a breathing test called spirometry, which measures how much air can be blown out in one second (FEV1). It is also not recommended for people who smoke or who stopped smoking within the past 6 months, because it has not been shown to be safe for them. A few cases of lung cancer occurred in clinical trials in people using Afrezza, mostly in people with a heavy smoking history. There were too few cases to know whether Afrezza played any role, but people with lung cancer, a past lung cancer, or a high risk of it should weigh this with their clinician. Afrezza is not used to treat diabetic ketoacidosis (DKA), a dangerous buildup of acids in the blood when the body lacks insulin. In type 1 trials, DKA was somewhat more common with Afrezza than with injected insulin. During an illness or infection, blood sugar should be checked more often, and the care team may switch mealtime insulin back to injections until recovery. Many medicines change blood sugar, so the prescriber and pharmacist should know about everything taken, including inhaled medicines and supplements. Beta-blockers (heart and blood pressure medicines such as metoprolol) can hide the warning signs of low blood sugar, and alcohol makes lows more likely. Taking Afrezza with pioglitazone (Actos), a diabetes pill in the thiazolidinedione group, can cause fluid retention and heart failure; new shortness of breath, swollen ankles or sudden weight gain should be reported.
Afrezza starts working within minutes, so its effect on after-meal blood sugar is seen from the first meal. Finding the right dose for each meal usually takes some weeks of adjustment, guided by blood sugar readings or a continuous glucose monitor. Changes in activity, meals, illness or other medicines can all shift the dose needed. In studies, adding Afrezza to oral diabetes medicines in type 2 diabetes lowered HbA1c (a blood test reflecting average blood sugar over about three months) more than an inhaled placebo. In type 1 diabetes, it lowered HbA1c somewhat less than injected mealtime insulin, and in a trial in children and teens it did not match injected insulin on that measure. For some people, fewer injections and quick action outweigh this; for others, injections give tighter control. Lung function is rechecked with spirometry after the first 6 months and then every year, even without symptoms. A drop of 20% or more from the starting value may lead the clinician to stop Afrezza, and breathing symptoms that persist usually mean stopping it. Its effects on the lungs beyond 2 years of use are not yet known. If blood sugar does not improve with higher doses, switching back to injected mealtime insulin is a reasonable option.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Afrezza (Inhaled Insulin), what you've noticed, or ask the community a question.